Arcellx (ACLX) Q3 2025 earnings summary

Executive summary

• Focused on developing innovative cell therapies for cancer and autoimmune diseases, with lead program anito-cel in pivotal Phase 2 and Phase 3 trials for multiple myeloma in partnership with Kite Pharma.

• Reported third quarter 2025 financial results, highlighting operational and financial performance.

• Net loss for the nine months ended September 30, 2025 was $170.8 million, with an accumulated deficit of $667.7 million.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $576.0 million as of September 30, 2025.

• Collaboration revenue was $20.6 million for the nine months ended September 30, 2025, down from $92.7 million in the prior year period.

• Collaboration revenue for Q3 2025 decreased to $4.9 million from $26.0 million year-over-year, mainly due to completion of dosing and manufacturing in a key trial.

• Research and development expenses increased to $123.5 million for the nine months, but fell to $35.1 million in Q3 2025 from $39.2 million year-over-year.

• General and administrative expenses rose to $86.5 million for the nine months and to $31.6 million in Q3 2025, reflecting increased commercial readiness and personnel costs.

Outlook and guidance

• Current cash and investments are expected to fund operations into 2028.

• Anticipates continued significant operating losses as research, development, and commercial readiness activities expand.

• Plans to advance clinical programs, pursue regulatory approvals, and expand pipeline, including new indications and product candidates.